This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
- Stacy Cooper, MD
- Clifford Takemoto, MD
- Charlotte Bloomberg Children’s Center, Johns Hopkins Hospital Baltimore, MD
Author Disclosure
Dr Cooper has disclosed no financial relationships relevant to this article. Dr Takemoto has disclosed a research grant from Novo Nordisk for hemophilia factor trials at Johns Hopkins University. This commentary does not contain discussion of unapproved/investigative use of a commercial product/device.
Von Willebrand disease (vWD) is an inherited bleeding diathesis. It is caused by quantitative or qualitative defects in von Willebrand factor (vWF), which functions to bind platelets to damaged endothelium and to stabilize factor VIII (FVIII). A range of mutations have been identified in this protein, encompassing the spectrum of single missense mutations to large deletions. Because of variation in the diagnostic criteria for vWD, debate exists regarding the prevalence; however, some studies estimate it to be as high as 1% to 2% of the population when including children and adults.
There are 3 major categories of vWD, classified as partial deficiency of vWF (type 1), functional defects (type 2), and complete deficiency of vWF (type 3). Type 2 can be further subcategorized based on the 4 subtypes of specific qualitative defects of the multimers (types 2A, 2B, 2M, and 2N). The different types of vWD vary in severity. Type 1 is the most common, an autosomal dominant disorder that comprises approximately 75% of vWD patients, and is usually confined to mild bleeding. Type 2 may demonstrate either dominant or recessive inheritance, and type 3 is autosomal recessive, with …
Individual Login
Institutional Login
You may be able to gain access using your login credentials for your institution. Contact your librarian or administrator if you do not have a username and password.